When was Metsera founded?

Metsera was founded in 2022 and raised its 1st funding round 2 years after it was founded.

Where is Metsera located?

Metsera is headquartered in New York City, United States.

How many employees does Metsera have?

As of Sep 30, 2026, the latest employee count at Metsera is 61.

Is Metsera a funded company?

Metsera is a funded company, having raised a total of $505M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 18, 2024.

How much is Metsera worth?

The last known valuation of Metsera was $***** as of Apr 03, 2026.

When was the latest funding round of Metsera?

Metsera's latest funding was a $***** Series B round on Nov 12, 2024, with participation from 14 investors. Its primary sector is Obesity. In United States, the Obesity sector has seen $651M in funding in 2026 to date.

Where does Metsera rank among its competitors?

Metsera ranks 8th amongst 125 active competitors, of which 34 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Enveda, which secured $311M in Sep, 2026.

Who are the top competitors of Metsera?

Metsera's top competitors include Kailera, Adocia and Enveda. Among them, Enveda secured the most recent funding round in September, 2026.

Metsera - 2026 Company Profile, Funding, Competitors & Financials

Q: Is Metsera an acquired company?

Metsera got acquired by Pfizer on Sep 22, 2025.

Metsera is an acquired company based in New York City (United States), founded in 2022. It operates as a Biopharmaceutical company focusing on medicines for obesity and metabolic diseases. Metsera has raised $505M in funding from investors like Venrock, Arch Venture Partners and Wellington, with last known valuation of $*****. The company has 125 active competitors, including 34 funded and 17 that have exited. Its top competitors include companies like Kailera, Adocia and Enveda.

Company Details

Biopharmaceutical company focusing on medicines for obesity and metabolic diseases. The company's portfolio unlock new treatment strategies through scalable, sustainable and personalized interventions for weight loss, weight maintenance and disease prevention.

Website: metsera.com
Email ID: *****@metsera.com

Key Metrics

Founded Year

2022

Location

New York City, United States

Stage

Acquired

Total Funding

$505M in 2 rounds

Latest Funding Round

Series B, Nov 12, 2024, $*****

Last Known Valuation

$***** as on Apr 03, 2026

Investors

Venrock & 17 more

Ranked

8^th among 125 active competitors

Employee Count

61 as on Sep 30, 2026

Similar Companies

Kailera & 130 more

Exit Details

Acquired by Pfizer (Sep 22, 2025)

View Metsera's full profile

Metsera is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
METSERA, INC. CIN: 2040807 , United States, Active	May 05, 2023	-	-	-

Metsera got acquired by Pfizer on Sep 22, 2025 at an acquisition amount of $*****.

Click here to take a look at Metsera's acquisition in detail

Metsera has raised a total funding of $505M over 2 rounds. Its first funding round was on Apr 18, 2024. Its latest funding round was a Series B round on Nov 12, 2024 for $*****. 14 investors participated in its latest round. Metsera has 18 institutional investors.

Here is the list of recent funding rounds of Metsera:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 12, 2024	8976371	Series B	4366697	3718133	6505854	4172680
Apr 18, 2024	1074764	Series A	5323784	7091234	Arch Venture Partners	F-Prime Capital & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Metsera's funding rounds and investors

Metsera's employee count trend

Metsera has 61 employees as of Sep 26. Here is Metsera's employee count trend over the years:

Uncover Metsera's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Metsera include Kailera, Adocia and Enveda. Here is the list of Top 10 competitors of Metsera, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Kailera 2024, Waltham (United States), Public	Developer of therapies for treating obesity and related conditions	$1B	Bain Capital Life Sciences, RTW Investments ... & 12 others	67/100
2nd	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	65/100
3rd	Enveda 2019, Boulder (United States), Series E	AI-based platform to decipher the chemistry of nature and develop new medicines	$845M	Premji Invest, Kinnevik & 36 others	64/100
4th	MBX Biosciences 2018, Carmel (United States), Public	Developer of drugs for the treatment of rare endocrine diseases	$216M	Deep Track Capital, Wellington & 9 others	63/100
5th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Praxis Capital, Smile Gate Investment & 10 others	63/100
6th	Zealand Pharma 1998, Glostrup (Denmark), Public	Developer of protein therapies for the treatment of diabetes and gastrointestinal diseases	-	Oberland Capital, Athyrium Capital Management ... & 9 others	62/100
7th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, ATW Partners & 6 others	61/100
8th	Metsera 2022, New York City (United States), Acquired	Biopharmaceutical company focusing on medicines for obesity and metabolic diseases	$505M	Venrock, T. Rowe Price & 16 others	61/100
9th	Congruence Therapeutics 2021, Montreal (Canada), Series B	Developer of therapeutics for the treatment of rare diseases	$136M	Amplitude, Orbimed & 9 others	60/100
10th	Carmot 2008, Berkeley (United States), Acquired	Developer of disease-modifying therapies to treat metabolic diseases	$386M	The Column Group, Deep Track Capital & 17 others	59/100